Parenteral Manual

Amphotericin B Lipid Complex (NON-FORMULARY)

Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Anifungal agent
Original Date: 
August 2005
Revised Date: 
November 2010

- Treatment of severe systemic/deep mycoses in patients:

  • who fail to respond to conventional amphotericin B (continuous fungemia or positive fungal cultures after a minimum trial of 10 days)
  • who develop nephrotoxicity after conventional amphotericin B (doubling of the serum         creatinine from baseline or a daily jump in serum creatinine of 30-50 mmol/L)
  • in whom conventional amphotericin B is contraindicated because of renal impairment        (creatinine clearance < 60 mL/min/1.73m2 )


Reconstitution and Stability: 
  • Available as a 5 mg/mL suspension. Protect from light
  • Allow suspension to come to room temperature.  Shake gently until there is no evidence of yellow settlement at bottom of the vial.  Filter through supplied 5 micron filter needle.
  • Punctured vial stable 2 days refrigerated
  • Diluted solution stable 48 hours refrigerated (plus an extra 6 hours at room temperature)
  • Unpunctured vial stable up to 1 week at room temperature if left out of fridge

- Solutions Compatible:  D5W

- Incompatible: saline solutions, ringers lactate, ciprofloxacin, gentamicin, meropenem, penicillin, fluconazole, granisetron, piperacillin.  Do not mix with other drugs or electrolytes (compatibility with these materials has not been established)


(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)

IV Direct NO
IV Intermittent Infusion YES

Syringe pump dilution: 1 mg/mL ONLY


Large volume pump

Usual dilution: 1 mg/mL
Fluid restricted patients: 2 mg/mL

Infusion time: 2 -4 hours (if > 2 hours, mix contents by gently rotating the infusion bag every 2 hours)

Infusion rate:  do not exceed 2.5 mg/kg/hour

IV Continuous Infusion NO

(For neonatal dosages, refer to Neonatal IV Drug Manual.)


  • 2.5 - 5 mg/kg IV once daily


  • 5 mg/kg/ IV once daily

It has been suggested that:

  • If CrCl is < 10 mL/min administer dose over 24-36 hours
  • Renal toxicity is dose-dependent.  There are no firm guidelines for dose adjustment based on serum creatinine levels.
Potential hazards of parenteral administration: 
  • Injection site - inflammation, thrombophlebitis
  • Flushing, hypotension
  • Transient chills and fever during infusion
  • Rash, pruritus, other allergic reactions, anaphylactoid reactions
  • Renal tubular acidosis, increased serum creatinine
  • Hypokalemia, hypomagnesemia, thrombocytopenia, leukopenia
  • Nausea, vomiting, headache
  • Monitor BUN, serum creatinine, liver function tests, serum electrolytes, CBC, ins and outs, signs of hypokalemia (muscle weakness, cramping, drowsiness, EKG changes)
  • Monitor vital signs throughout infusion
  • Premedication with acetaminophen and diphenhydramine may help reduce severity of side effects.
  • Flush line with D5W prior to infusion
  • Consider sodium loading to minimize the nephrotoxic risk
    - Patient must be euvolemic with a normal serum sodium
    - Contraindication - significant caridac, renal or respiratory compromise
    - Procedure - infuse sodium chloride 0.9% 10 mL/kg (1.5 mmol Na/kg) IV over 60 minutes prior to  amphotericin B Lipid Complex infusions
    - Flush IV lines with dextrose solution prior to administration of Amphotericin B Lipid Complex due to incompatibility with saline containing solutions
    - Continue sodium loading for the duration of Amphotericin B Lipid Complex therapy

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.